The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Texas MPN Workshop 2022 | Tagraxofusp: a promising agent for the treatment of pediatric BPDCN

Name: Tagraxofusp: a promising agent for the treatment of pediatric BPDCN
Uploaded: 2022-08-27T00:00:00Z
Duration: 1 min 16 s
Description: Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the challenges associated with treating pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) and the promise of tagraxofusp for the treatment of these patients. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Naveen Pemmaraju • 27 Aug 2022

Texas MPN Workshop 2022

Blastic Plasmacytoid Dendritic Cell Neoplasm Myeloproliferative Neoplasms Rare Diseases Tagraxofusp

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the challenges associated with treating pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) and the promise of tagraxofusp for the treatment of these patients. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.